Adagen Global Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Adagen is the brand name for pegademase bovine, an enzyme replacement therapy used to treat severe combined immunodeficiency (SCID) resulting from adenosine deaminase deficiency. It supports immune function in individuals with SCID by replenishing the missing enzyme required for normal immune system development, thereby helping to lower the risk of life-threatening infections.

The main product forms of Adagen include pre-filled and vial presentations. Pre-filled formulations are supplied in ready-to-use syringes or devices, offering convenience and accurate dosing for patients. Adagen is primarily used to treat clinical conditions such as severe combined immunodeficiency (SCID) and other rare genetic disorders, and it is utilized across settings including hospitals and healthcare institutions, specialty clinics, home healthcare services, and research institutions.

Tariffs have had a limited yet notable impact on the adagen market by increasing costs for imported enzyme production materials and cold chain logistics. These effects are most significant in europe and asia pacific regions dependent on international supply. Higher tariffs can influence pricing stability for rare disease therapies. However, they are also encouraging regional production partnerships. This improves long term supply reliability for critical enzyme treatments.

The adagen market research report is one of a series of new reports from The Business Research Company that provides adagen market statistics, including adagen industry global market size, regional shares, competitors with a adagen market share, detailed adagen market segments, market trends and opportunities, and any further data you may need to thrive in the adagen industry. This adagen market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The adagen market size has grown strongly in recent years. It will grow from $0.09 million in 2025 to $0.1 million in 2026 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to lack of alternative therapies for ada scid, early success of enzyme replacement therapy, improved patient survival rates, orphan drug regulatory incentives, adoption by specialty immunology centers.

The adagen market size is expected to see strong growth in the next few years. It will grow to $0.13 million in 2030 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to advancements in genetic screening, rising rare disease awareness, expansion of specialty immunology clinics, supportive reimbursement frameworks, increased investment in orphan drugs. Major trends in the forecast period include sustained use in rare immunodeficiency disorders, growing emphasis on enzyme replacement therapies, increasing long term scid patient management, rising integration of supportive immunology care, enhanced focus on pediatric rare disease treatment.

The growing adoption of precision medicine is expected to drive the growth of the Adagen market in the coming years. Precision medicine is an advanced healthcare approach that customizes medical treatments and preventive strategies based on individual patient characteristics. The increased adoption of precision medicine is supported by advancements in genomic technologies, wider availability of biomarkers, integration of artificial intelligence in healthcare, and rising demand for targeted therapies aligned with patients' genetic profiles. Adagen supports precision medicine by providing a targeted enzyme replacement therapy specifically developed for patients with severe combined immunodeficiency (SCID) resulting from adenosine deaminase deficiency, highlighting the value of personalized treatments for rare genetic disorders. For example, in February 2024, according to data from the Personalized Medicine Coalition (PMC), a US-based nonprofit umbrella organization, the FDA approved 16 new personalized treatments for rare diseases in 2023, a notable increase compared to six approvals in 2022. As a result, the expanding adoption of precision medicine is fueling growth in the Adagen market.

Rising healthcare expenditure is also expected to propel the Adagen market going forward. Healthcare expenditure refers to the total financial resources spent on medical services, treatments, and healthcare infrastructure by individuals, governments, and organizations. The increase in healthcare spending is driven by factors such as advancements in medical technology, an aging population, higher prevalence of chronic diseases, demand for specialized therapies, and overall medical cost inflation. Adagen contributes to healthcare expenditure by offering specialized enzyme replacement therapy for rare genetic conditions, leading to greater investment in research, patient care, and improved access to treatments for disorders such as severe combined immunodeficiency. For instance, in May 2024, according to the Office for National Statistics, a UK-based government department, healthcare spending in the UK increased by 5.6% between 2022 and 2023, compared with growth of 0.9% in 2022. Total UK healthcare expenditure reached approximately $317.63 billion (£292 billion) in 2023. Therefore, increasing healthcare expenditure is supporting the growth of the Adagen market.

The rising diagnosis of rare diseases is further expected to support the expansion of the Adagen market. Rare diseases are conditions that affect fewer than one in 2,000 individuals and are often genetic in nature, with significant health consequences. The growing identification of rare diseases is driven by improvements in genetic testing technologies, greater awareness among healthcare professionals, enhanced healthcare infrastructure, and expanded international collaboration in rare disease research. Adagen plays a role in addressing the growing diagnosis of rare diseases by providing targeted enzyme replacement therapy for severe combined immunodeficiency, thereby increasing awareness, encouraging early diagnosis, and supporting broader research into rare genetic disorders and their treatment options. For example, in February 2024, according to Genetic Alliance UK, a UK-based national alliance of organizations, rare conditions affect more than 3.5 million people in the UK, with one in 17 individuals experiencing a rare condition at some point in their lives. Of the approximately 7,000 identified rare diseases, around 70% affect children, and more than 30% of affected children die before the age of five due to the severity of these conditions. Consequently, the increasing diagnosis of rare diseases is driving growth in the Adagen market.

Major companies operating in the adagen market are Leadiant Biosciences Inc.

North America was the largest region in the adagen market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adagen market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the adagen market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The adagen market consists of sales of single-use vials and ready-to-use syringes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Adagen Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses adagen market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for adagen ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The adagen market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product: Pre-filled; Vial
• 2) By Clinical Indication: Severe Combined Immunodeficiency (SCID); Other Rare Genetic Disorders
• 3) By End User: Hospitals And Healthcare Institutions; Specialty Clinics; Home Healthcare Services; Research Institutions
• Companies Mentioned: Leadiant Biosciences Inc.
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.